EMPLOYMENT AGREEMENTEmployment Agreement • November 29th, 2021 • Blue Water Vaccines Inc. • Pharmaceutical preparations • Ohio
This EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of July [●], 2021 by and between Blue Water Vaccines, Inc., a Delaware corporation (the “Company”) and Jon Garfield (“Executive”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 29th, 2021 • Blue Water Vaccines Inc. • Pharmaceutical preparations • Ohio
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and effective as of June , 2021 (the Effective Date”) by and between Blue Water Vaccines ___________________________________, having a principal place of business at 201 E Fifth Street, Suite 1900 Cincinnati, OH 45202 (“Company”), and Children’s Hospital Medical Center, d/b/a Cincinnati Children’s Hospital Medical Center (“CHMC”), having a principal place of business at 3333 Burnet Avenue, Cincinnati, Ohio 45229-3039, USA.
EXCLUSIVE LICENSE AGREEMENT BETWEENLicense Agreement • November 29th, 2021 • Blue Water Vaccines Inc. • Pharmaceutical preparations • Tennessee
THIS LICENSE AGREEMENT (the “Agreement”) is entered into as of January 27, 2020 (the “EFFECTIVE DATE”) by and between ST. JUDE CHILDREN’S RESEARCH HOSPITAL, INC., a Tennessee not-for-profit corporation having an address at 262 Danny Thomas Place, Memphis, TN 38105 (“ST. JUDE” or “LICENSOR”), and Blue Water Vaccines, Inc., a Delaware corporation, having an address at 2014 Courtland Avenue, Cincinnati, OH 06830 (“COMPANY”) (ST. JUDE and COMPANY hereinafter each referred to as a “PARTY”, or collectively referred to as the “PARTIES”) with respect to the following:
DATED 16th July 2019Agreement • November 29th, 2021 • Blue Water Vaccines Inc. • Pharmaceutical preparations
The Licensed Technology is connected with QUI Project Numbers: 13709, 16867, 16870 and 16872 which comprise components from the Haemagglutinin proteins of Influenza A Group 1, Influenza Group 2 and Influenza B and a VLP delivery system which together form a candidate Universal Influenza vaccine. The Licensee wishes to acquire a licence to the Licensed Technology and QUI is willing to license the Licensed Technology to the Licensee, on the terms of this agreement.
